Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are ...

Yet the disparities by sex, race/ethnicity, and location pale in comparison to a striking overall lack of adoption.

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Approaches to dietary interventions among patients with obesity can differ depending on whether they are also being treated ...

CVS Health's pharmacy benefits manager said weight-loss drugs from rival drugmaker Novo Nordisk will become the preferred ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

"The results provide strong evidence that semaglutide can help patients by improving liver health and addressing underlying ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...

GLP-1 drugs such as Ozempic and Wegovy have been generating a buzz. Initially developed to treat type 2 diabetes, these drugs are now also recognized ...

Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.